Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$16 Mln
P/E Ratio
--
P/B Ratio
0.61
Industry P/E
--
Debt to Equity
0
ROE
-1.55 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
-2.18
CFO
$-75.47 Mln
EBITDA
$-218.20 Mln
Net Profit
$-232.43 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Biovie Inc (BIVI)
| -59.01 | -26.80 | -60.01 | -83.15 | -72.59 | -54.49 | -41.51 |
|
BSE Sensex*
| 2.39 | 4.18 | 4.86 | 8.78 | 11.89 | 20.62 | 11.13 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Biovie Inc (BIVI)
| -83.89 | -83.78 | 72.67 | -74.02 | 394.86 | -0.35 | -81.27 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.48 | 9,808.03 | 20.22 | 23.13 | |
| 282.28 | 8,956.09 | 22.08 | 58.42 | |
| 25.74 | 9,559.25 | -- | -28.77 | |
| 101.74 | 10,030.35 | 30.81 | 14.16 |
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease. The company develops BIV201 for the treatment of ascites due to chronic liver... cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2 clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada. Address: 680 West Nye Lane, Carson City, NV, United States, 89703 Read more
President, CEO & Director
Mr. Cuong Viet Do M.B.A.
President, CEO & Director
Mr. Cuong Viet Do M.B.A.
Headquarters
Carson City, NV
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Biovie Inc (BIVI) stood at $ 27 Mln as on 31-Dec-24
The share price of Biovie Inc (BIVI) is $0.82 (NASDAQ) as of 22-Apr-2025 16:18 EDT. Biovie Inc (BIVI) has given a return of -72.59% in the last 3 years.
Biovie Inc (BIVI) has a market capitalisation of $ 16 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Biovie Inc (BIVI) is 0.61 times as on 22-Apr-2025, a 73% discount to its peers’ median range of 2.25 times.
Since, TTM earnings of Biovie Inc (BIVI) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Biovie Inc (BIVI) and enter the required number of quantities and click on buy to purchase the shares of Biovie Inc (BIVI).
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease. The company develops BIV201 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2 clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada. Address: 680 West Nye Lane, Carson City, NV, United States, 89703
The CEO & director of Mr. Cuong Viet Do M.B.A.. is Biovie Inc (BIVI), and CFO & Sr. VP is Mr. Cuong Viet Do M.B.A..
There is no promoter pledging in Biovie Inc (BIVI).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Biovie Inc (BIVI) | Ratios |
|---|---|
|
Return on equity(%)
|
-127.85
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Biovie Inc (BIVI) was $0 Mln.
$0.03
(
